# Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

> **NCT03353831** · PHASE3 · COMPLETED · sponsor: **AGO Research GmbH** · enrollment: 574 (actual)

## Conditions studied

- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab
- **DRUG:** Chemotherapy
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT03353831
- **Lead sponsor:** AGO Research GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-11
- **Primary completion:** 2025-03-11
- **Final completion:** 2025-03-11
- **Target enrollment:** 574 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03353831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03353831, "Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03353831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*